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Summary 
Epstein-Barr virus (EBV) as a member of the herpesvif 
family persists lifelong in the human body and causes diseas 
associated with virus replication (infectious mononucleos' 
oral hairy leukoplakia) as well as neoplastic conditions such 
nasopharyngeal carcinoma, B-cell lymphoma, Hodgkin's di 
ease associated with viral latency. This complex biolo. 
relates to a highly regulated control of the persisting virt 
Still , E B V is lytically produced in certain compartments of tt 
human body. Epithelial cells were found to be of key imp^ 
tance for this. Various routes (cell fusion, IgA recept^ 
mediated uptake) were described for E B V to enter epithel1 
cells in the absence of C R 2 receptor. Vi ra l entry into eel 
however, via C R 2 receptor fusion or IgA mediated was 
found to be sufficient for viral production. The molecul1 
mechanisms for the lack of viral production in most tarf1 
cells are primarily the presence of silencer activities and t" 
early elimination of cells entering the lytic cycle. Only tern 
nally differentiated epithelial cells are capable of support^ 
an efficient lytic cycle of E B V replication. EBV-mediated si1 
pression of apoptosis as well as down-regulation of cellular aj 
viral gene products, such as H L A molecules, which med^ 
recognition by the immune system, are important contrifr 
ing factors to the development of these neoplasias where vi-
genes, possibly via interaction with anti-oncogenes, such^ 
p53, in context with genetic and environmental factors pl# 
key role. Novel diagnostic tools and a vaccine have been deV' 
oped which could help to control EBV-related diseases. 
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When Dennis Burkitt approached Epstein 
in 1961 for help in search for a common prin-
ciple involved in the generation of clinically 
very divergent neoplasias, a new field in virol-
ogy started. Several achievements and discov-
eries, sometimes favored by luck, identified 
the first virus related to human neoplasia. 
Epstein's and Pulvertaffs groups succeeded 
for the first time in growing lymphoid cell 
hnes out of lymphoma tissue [Epstein and 
B arr, 1964a; Pulvertaft, 1964]; Epstein's 
group detected herpesvirus-like particles in 
such cells [Epstein and Barr, 1964b], Werner 
and Gertrude Henle identified this virus as a 
new species of the herpesvirus family [Henle 
and Henle, 1966] and V . Diehl , when working 
w i t h the Henles, found, when following up the 
seroconversion of a lab technician, that this 
new virus, now named after its first observers 
Epstein-Barr, was the cause of infectious 
mononucleosis (IM) [Henle et al., 1968]. Pope 
e t al. [1967] were able to demonstrate that 
v i r u s from I M patients can readily immortal-
ize peripheral B lymphocytes. The newly de-
veloped technique of nucleic acid hybridiza-
tion resolved the puzzle, that many cell lines 
^ i d not produce any virus or early or late anti-
gens related to viral replication. However, Ep-
stein-Barr virus (EBV) D N A could be regular-
•v demonstrated in D N A from cell lines and 
tumor biopsies. When sera from patients with 
Nasopharyngeal carcinomas (NPC) were used 
a s control to Burkitt lymphoma and other 
e r a , the regular and dramatically elevated 
antibody levels to EBV-related antigens sug-
f e s ted a causative involvement of E B V also in 
r h i s malignancy [Old et al., 1968], where epi-
thelial cells are the proliferative cell type. Is 
i*he presence of E B V an epiphenomenon in-
e d u c e d into the tumor tissue by infiltrating 
^ p h o c y t e s , or is it really in the epithelial 
) t u rnor cells? A refinement of nucleic acid 
hybridization technique allowing the detec-
• 1 Q n of specific nucleic acid in tissue sections 
was developed to answer this question [Wolf 
et a l , 1973]. The linkage of E B V with I M as 
primary disease and B-cell lymphomas and 
N P C [Wolf et al., 1973] raised many ques-
tions to the molecular biologists, e.g.: 
- What does E B V do to the human host? 
- H o w does E B V enter the body and its host cells? 
- W h y does the presence of efficiently infectable tar-
get cells not k i l l al l such cells and produce fatal dis-
ease and still ensure spreading o f the virus by life-
long shedding o f E B V ? 
- H o w does the immune system control E B V - i n -
fected cells? 
- H o w does E B V immorta l ize and transform its host 
cells? 
- What are the mechanisms permit t ing persistence of 
E B V ? 
- H o w can we control serious EBV-re la ted diseases? 
The number of diseases related to E B V has 
grown during the years. Whereas the primary 
infection has a tendency to milder symptoms 
in younger children, the typical picture is I M 
with the characteristic features fever, high leu-
kocyte counts (from 20,000 up to 80,000) and 
sore throat. There is a tendency to more 
chronic courses lasting several months, in par-
ticular for older patients. The reason for rare 
fatal cases where virus replication has been 
detected in the liver is unclear [Deutsch et al., 
1986]. 
A clear gentic factor is involved in Duncan 
syndrome where a locus of the X chromosome 
determines a fatal outcome of E B V infection 
[Purtilo et al., 1975; Skare et al., 1987]. 75% 
of males die from fatal I M , the remainder die 
from a variety of EBV-related conditions, 
mostly of B-cell lymphomas; 70% die by 10 
years of age, 100% are dead by 40 years. 
Whereas so far consequences of primary 
E B V infection were discussed, oral hairy leu-
koplakia is a secondary disease related to E B V 
replication [Greenspan et al., 1985] which oc-
curs in discrete areas of the tongue, due to 
activation of E B V in maturing epithelial cells 
Table 1. Ce l l proliferation-related condit ions 
1 B-cell l ymphoma 
- Polyclonal 
- M o n o c l o n a l : B u r k i t f s l ymphoma 
2 T-cel l l ymphoma 
- A I L D angioimmunoblas t ic lymphadenopathy 
wi th dysproteinemia [Weiss et al . , 1992] 
- Lethal mid l ine granuloma [Harabuchi et al . , 
1990] 
3 Hodgkin ' s l ymphoma (nodular sclerosing) 
[Weiss et al. , 1987, 1989] 
4 Nasopharyngeal carc inoma 
in the absence of an intact cellular immune 
system [Becker et al., 1991]. 
More than lytic infection, induction of cel-
lular proliferation is a characteristic feature of 
E B V . Besides Burkitt's lymphoma, where E B V 
is present in about 25% of worldwide sporadic 
cases, it is present in more than 90% of 
endemic cases in Africa. Because chromosom-
al translocations involving the myc oncogene 
are invariably present regardless of the E B V 
status [Taub et al., 1982; Erikson et al., 1982], 
E B V is seen by many as a favoring rather than 
in the strict sense causative factor. Consider-
able speculation has been published to this 
point [Lenoir and Bornkam, 1987], but the 
apparently high load of E B V in children, who 
later develop Burkitfs lymphoma (BL) in Afr i -
ca [de The et al., 1978] might suggest that E B V 
gives some additional growth advantage to 
already immortalized cells or even may be 
involved in disturbing the chromosomal rear-
rangement, which through the activity of myc 
alters the immunologic features of the cells and 
makes them less recognizable by immune 
mechanisms. The latter function would ex-
plain why cells of the B L type have not been 
established by infection in vitro of EBV-nega-
tive peripheral or stem cells, where in vitro 
class switch in the immunoglobins is usually 
not observed. Furthermore, in vitro the rigt" 
selective pressure by specific T cells is ru 
exerted. 
For other neoplastic diseases with EB 
association, even less is known on the mech* 
nisms of development (table 1). 
For N P C exclusive epidemiological studio 
suggest a genetic component, possibly relate 
to the H L A family and environmental facto 
involving ingredients of certain medicifl 
herbs, voltaile nitrosamines from preserve 
food and low vitamin C content in the di 
[Zeng et al., 1988, 1993; Poirier et al., 198 
L u et al., 1990; Bouvier et al., 1991; Hubert 
al., 1993]. 
How Does EBV Enter Its Host and Its 
Host Cells? 
A usually pleasant event, kissing, is tl* 
best established route of infection, althous. 
transplantation and blood transfusion are 
very efficient in virus transmission, otft 
routes including sexual intercourse are po$!< 
ble, due to demonstration of E B V in vagif 
fluid, but are not definitely proven [Sixbey 
al., 1986] 
For the cellular level we know less ab^ 
pleasure, but infection of lymphocytes via t 
cellular receptor CD21 (CR2) for comp 
ment C3d ends in an immortalizing liai* 
[Frade et al., 1985; Nemerow et al., 1987]. 
Is CD21 mandatory for infection? If • 
how can epithelial cells or T cells be infecK-
EBV-infected B cells entering a lytic cyc l^ 
viral replication have been shown to effici^ 
ly fuse to a wide variety of cells [Bayliss <*; 
Wolf, 1980, 1981]. Therefore, the entry pff 
lem of E B V into cells does not seem to 
limiting factor. Recently, an IgA-mediated^ 
try via a polymeric IgA receptor on polari^ 
epithelial cells has been described as an 
tional entry mechanism [Sixbey an V 
Table 2. Overv iew of various 
subsets of latent E B V gene 
products 
Type of Promoter 
latency usage 
Lat 
Lat III 
F p 
Lat II F p ( L R S ) 
W p < 2 4 h 
C p 
Lat IV W p 
Expressed 
gene products 
Tissue or cell 
E B N A 1 
E B E R 
E B N A 1 
L M P 1 , L M P 2 B 
L M P 2 A 
E B E R 
B A R F O transcripts 
E B N A 1 - 6 
L M P L L M P 2 B 
L M P 2 A 
E B E R 
L M P 2 A 
B u r k i t f s l ymphoma 
biopsy and fresh cell lines 
nasopharyngeal 
carcinoma 
lymphoblas toid cell lines 
passaged B u r k i t f s 
l ymphoma cell lines 
peripheral b lood B 
lymphocytes 
1 9 9 2 ] . As EBV-specific IgA antibodies are 
transiently present upon primary infection, 
f h l s could in rare events lead to epithelial cell 
i n f ect ion. The high IgA antibody levels in 
patients, however, are a consequence 
; a t h e r than a cause of N P C . 
Why Does the Presence of Efficiently 
Infectable Target Cells Not Kill All Such 
cells and Produce Fatal Disease and Still 
Ensure Spreading of the Virus by Lifelong 
Shedding of EBV? 
A f t e r entry, the virus apparently undergoes 
Jimited replication of its D N A [Yates and 
->uan, 1991]. It persists usually as multiple 
of closed circular D N A . For persis-
e n c e during cell division the expression of 
: B N A 1 is mandatory. It binds to the BamC 
T 1 8 1 n of piasmid replication (oriP). Further-
n o r e - nuclear matrix attachment regions 
a v e been identified [Janklevich et al., 1992]. 
?ePendent on the cell type, various subsets of 
. U e n l E B V gene products are expressed. Ta-
ble 2 gives an overview. Whereas in B L tumor 
cells the stage Lat I with only E B N A 1 as viral 
gene product is favored, in lymphoblastoid 
cell lines (LCL's ) (EBV-immortalized non-
malignant B cells) Lat III with the whole set of 
E B N A and L M P expression is established. 
If a cytolytic virus would efficiently repli-
cate in a readily accessible and easily infecta-
ble cell type, this could potentially ki l l the 
host. A n d indeed, E B V replication is strong-
ly down-regulated in B-lymphoblastoid cells 
as well as in less differentiated epithelial 
cells. Only terminally differentiated epithe-
lial cells seem to be capable of efficiently 
supporting the E B V lytic cycle. This can be 
seen in biopsies from parotid glands [Wilmes 
and Wolf, 1981; Wol f et al., 1984] and oral 
hairy leukoplakia [Becker et al., 1991] and is 
supported by experimental evidence [Mar-
schall et al., 1991]. The mechanisms for this 
virus host cell interaction are subject of de-
tailed studies. 
Transcription of B Z L F 1 , a major imme-
diate early gene of E B V , is negatively con-
trolled by more than one silencer region up-
Fig. 1. a Band shift experiment with subcloned 
fragments (BamWl/BaW = Z200 and BaWSphl = Z120) 
of the distal BZLF1 promoter. The DNA fragments 
were incubated with nuclear protein extracts and the 
resulting protein-DNA complexes analyzed on a native 
polyacrylamide gel. Competitor DNA was added to 
identify specific and unspecific binding of proteins. 
Protein extract from EBV-negative BJAB cells (BL), 
EBV-positive latently infected Raji- and TPA-treated 
(EBV replication induced) Raji cells (BL). Specific 
(Z120, Z200) and unspecific (pUC18) competitor 
DNA was added as indicated. The arrow indicates a 
specific protein-DNA complex with both promoter 
fragments (lanes 3, 5, 10, 12) that does not form in 
TPA-treated lymphoid cells, where lytic replication of 
the virus is induced, b Drawing of negative and posi-
tive regulatory elements in the promoter of BZLF1. 
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HI 
stream of the promoter (fig. lb). Two types of 
silencer elements have been identified so far 
in this region by testing the regulative modules 
in functional assays [Flemington and Speck, 
1990; Montalvo et al., 1991]. A consensus 
binding site for a negative regulative cellular 
factor, Y Y 1 , has been described [Shi et al., 
1991]. We have now found another kind of reg-
ulatory element (HI element, consensus * 
quence: 5 - ( C A T N ) A C A G A T / G G A - 3 ) in $ 
distal promoter region, which does not dire^ 
confer negative regulation of a heterology 
promoter but does interfere with flanking p°* 
tive regulatory sequence motifs [Schwarzm^ 
et al., unpubl.]. Further, we could demonsttf 
that in this region of the promoter the prote1 
inding pattern changes with the ability of 
B V to switch to the lytic cycle (fig. la). 
Even i f the transactivator Zta (also termed 
Z L F 1 , Z E B R A , Z , EB1) is translated from 
the B Z L F 1 reading frame, it is not sufficient 
in all cells to induce a full lytic cycle. While it 
does so in BL-type cells and fully differen-
tiated epithelial cells, it is inactive in L C L ' s . 
Vhereas Zta alone induces lytic proteins in 
J L cells, it is not able to induce important lyt-
ic gene products in L C L ' s , among them the 
lytic transactivator Rta (also termed B R L F 1 , 
[Bogedain et al., unpubl.] (fig. 2, 3). Rta is 
assumed to be crucial for the onset of the lytic 
cycle in lymphoid cells ( L C L ) [Zalani et al., 
1992]. 
For the B S L F 2 / B M L F 1 regulatory up-
stream region, a silencing function was de-
tected in latently infected B-lymphocytes 
w h i c h was shown to be inefficient in E B V -
negative lymphoid and epithelial cells [Mar-
sha l l et al., 1990]. Using teratocarcinoma 
c e Hs as an in vitro differentiation model, 
*e down-regulation of E B V promoter activi-
ty was demonstrated for unstimulated imma-
ture cells, whereas specific transcriptional re-
p °nses became obvious during proceed 
R 9 - 3 . Schematic illustration 
Seating gene regulation events of 
h e early phase of the lytic cycle in 
cells and LCLs observed follow-
e*pression of the transactiva-
D r s Zta and Rta with recombinant 
^ccinia viruses. The arrows give 
Be activities exerted by the trans-
a c t o r s in Zta (Z) and Rta (R) on 
^ e gene products of the reading 
rames BSLF2/BMLF1 (M) and 
|ALF2 (pi 38) of the early group. 
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Fig. 2. Western blot analysis of each one BL cell 
line (e.g. Jijoye) and LCL. The cell lines were infected 
with vaccinia wild-type (strain WR, VWR), recombi-
nant vaccinia viruses Z-Vac and R-Vac for expression 
of Zta and Rta, respectively, as given in the figure. 
Blots were screened for expression of Rta using a poly-
clonal rabbit antiserum. Rta has a size of 96/92 kD and 
is induced by Zta in the BL line, but not in the LCL. 
BL cells 
Akata, Daudi.Eli, 
Jijoye, P3HR-1, Raji 
Lat I, Lat III 
LCL's 
5 established lines 
Latlll 
ing cell differentiation [Marschall et al., 
1991]. 
In view of biology, the activation of the lyt-
ic cycle only in differentiated cells, as in the 
salivary ducts of the parotid gland [Wolf et al., 
1984], a proven site of lifelong E B V replica-
tion in the presence of an efficient immune 
control, limits viral production to very few 
privileged sites without causing any lesions. 
This seems to be a prerequisite for a virus sys-
tem, which involves long-term shedding of 
virus causing an efficient spread in the popu-
lation. The success of this V i r a l strategy' is 
reflected in over 90% seropositive adults. 
Is the Parotid Gland the Major Site of 
Persistence of EBV? 
Even when bone marrow recipients are 
treated by radiation, oral shedding of virus 
continues for several months, but eventually 
declines [Gratama et al., 1988, 1992]. There-
fore, one has to assume a dynamic process 
with the salivary gland being a major site of 
E B V production and persistence, which needs 
to be occasionally replenished with virus from 
lymphoid cells of L C L or possibly memory 
cell type with their very restricted replication-
supporting potential. 
How Does the Immune System Control 
EBV-Inf ected Cells? 
The presence of cells capable of lytic ex-
pression of E B V and of cells which harbor 
E B V genomes and proliferate would consti-
tute dangerous conditions for the host. Indeed 
the suppression of the immune system, for 
example as a consequence of infection with 
H I V , reveals such consequences. Sites of per-
sistence of E B V in cells with lytic potential 
develop into lesions due to EBV-related cell 
lysis (oral hairy leukoplakia) [Greenspan 
al., 1985]. L C L - l i k e peripheral blood lymph 
cytes develop into polyclonal lymphoid 
which are likely targets for the control throu-
the immune system. Because most E B V po-
tives have no antibodies to the group of e# 
antigens, typically consisting of a group 
replication-related enzymes, elimination 
cells entering a lytic cycle likely occurs at 
earlier phase of the viral life cycle, so e# 
antigens are not synthesized and therefore-
not available antigens. Because latently 
fected cells are not eliminated from the bo 
altogether, these cells seem to follow a co' 
mon strategy to escape immune control. F r c 
the panel of latent antigens (table 2), seve 
of them were identified as targets for c) 
toxic T lymphocytes. The long (spliced) V l 
sion of L M P , which is preferentially ' 
pressed in nonmalignant L C L - l i k e cells, is r< 
ognized by cytotoxic T lymphocytes (C? 
[Markert et al., unpubl. data] (fig. 4a). Thi> 
in contrast to malignant B L cells, which ' 
press the nonimmunogenic (fig. 4a) truncal 
form [Modrow and Wolf, 1986]. In additu 
E B N A 2 , 3a, 3b, and 3c were identified' 
C T L targets [Murray et al., 1990; Burrovtf 
al., 1990; Gaviol i et al., 1992]. Howev1 
E B N A 1 , possibly because ol its homology 
cellular proteins [Heller et al., 1982; Seibl 
Wolf, 1985], was found not to be recogni r 
by C T L . In B L cells several stages of v l 
latency are defined [Rowe et al., 1987] ( 
ble 2). Cells persisting in stage Lat I sht)l 
efficiently escape immune recognition. ^ 
cells in Lat I are able to directly enter the 1) 
cycle, the group of immediate early prot^1 
typically transactivators, meet well criteria 
being main targets for T-cell response [B° 
dain et al., unpubl. data] (fig. 4b, c). To • 
dress this question, the lytic transactive 
genes Zta (Z, B Z L F 1 , Z E B R A ) , Rta J 
B R L F 1 ) , I'ta (BILF4) , and M (BSl 1 ' 
B M L F 1 , EB2, M S - E A ) have been cloned i* 
Wo 117 Bogcd a 1 n / Schwa r / m a n n 
a b c 
50:1 10:1 2:1 50:1 10:1 2:1 50:1 10:1 2:1 
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Fig. 4. C T L response against autologous target cells expressing L M P (a), Z ta (b) and Rta 
(c) by recombinant vaccinia virus expression. The results are percent specific cytotoxicity 
observed at three eficctontarget (E:T) ratios and were obtained in 5 1 Cr-release assays, a The 
response obtained against the long version of L M P is indicated ( • ) . Target cells expressing the 
truncated version of L M P ( • ) and infected with vaccinia wild-type (O) were not lysed. b C T L 
lines were stimulated for weeks with autologous L C L . One line lysed Zta expressing target cells 
( • ) . The vaccinia wild-type negative control is indicated (O). Th i s C T L line was restimulated 
with Z-Vac-infected autologous L C L for a further 2 weeks which resulted in an elevated signal 
( • ) . • = V a c c i n i a wild-type negative control , c C T L response against cells expressing R ta ( • ) . 
O = V a c c i n i a wild-type negative control . 
'accinia virus and used to infect E B V ge-
nome-positive B cells to serve as targets for 
syngeneic T cells, which have been expanded 
V l t h U--2 in the presence of induced and irra-
^ated B cells. A clear cytotoxic response 
r o u l d he seen for the immediate early transac-
i l vators Zta and Rta (fig. 4b, c). 
1 The incomplete elimination of carrier lym-
phocytes of the L C L type and of B L cells likely 
l a s more complex reasons. It has been shown 
hat BL cells either do not produce L M P or at 
i n o s t m a truncated form [Modrow and Wolf, 
in addition, certain peripheral blood 
r e , l s have been identified, which do not ex-
r ^ s L M P . Furthermore, even in cell lines 
j ^ v n to express L M P , onlv less than 10% of 
a l l . • *Hs shov a high level of L M P expression, the 
F expresses L M P at most to a much lesser 
i e m [Modrow and Wolf, 1986; Modrow et 
al., 1987]. It has been shown by several groups 
that absence of L M P would allow such cells to 
escape specific killing [Jilg et al., 1988, 1989; 
Thorley-Lawson and Israelsohn, 1987]. Other 
latent gene products are either absent or, in the 
case of E B N A 1 , have a high homology to a cel-
lular gene and are not targets for T-cell-me-
diated cell lysis. In addition, in the case of B L 
the expression of H L A is altered and usually 
down-regulated [Jilg et al., 1991]. For the A11 
allele of H L A class I, the down-regulation was 
described by Klein and co-workers [cf. Masuc-
ci et al., 1987]. Rickinson's group found sever-
al cell adhesins ( L F A 3 , I C A M 1 ) to be ex-
pressed at lower levels [Gregory et al., 1988]. 
Cellular and viral gene expression together 
control elimination of EBV-infected cells. 
However, there are more properties of E B V , 
which permit or at least favor its persistence 
Table 3. Properties o f E B V : mechanisms important 
dur ing establishment of persistence 
How Does EBV Immortalize and 
Transform Its Host Cells? 
1 E B N A 1 is not immunogenic (related to host 
protein) [Seibl and Wolf , 1985; Hel ler et al . , 1982] 
2 L M P 1 absent or truncated in B L cells 
[ M o d r o w and Wolf , 1986] 
3 B u r k i t f s l ymphoma cells (not a direct effect o f 
E B V ) : down-regulation of: 
- H L A class II [Masucci et al . , 1987] 
- H L A c l a s s I f J i l g e t al . , 1991] 
- L F A 3 , I C A M 1 [Gregory et al . 1988] 
4 B C R F 1 gene product has homology to IL-10: 
block o f I L - 2 and I F N - y [Hsu et al . , 1990] 
Enhancement o f C T L and N K cells [Stewart and 
Rooney, 1992] 
5 E B E R transcripts inhibi t I F N - i n d u c e d k d s - R N A 
activatable phosphokinase' (p68) [Clarke et al . , 
1990] 
6 E B N A 2 blocks induct ion of I F N 
7 a) L M P 1 induces cellular bcl2: suppression of 
apoptosis [Henderson et al . , 1991 ] 
b) B H R F 1 homology to bcl2: suppression of 
apoptosis? [Reed et al . , 1989; Lee and Yates, 
1992] 
8 V i r u s product ion in privileged sites [Sixbey et al . , 
1986; W o l f et al . , 1984; Greenspan et al . , 1985; 
Becker et al . , 1991] 
in the host. These additional mechanisms (ta-
ble 3) might be particularly important during 
the establishment of infection where unspe-
cific defense mechanisms of the host, such as 
interferons [Clarke et al., 1990], could other-
wise result in fast and complete clearance of 
infecting E B V from the receiving organism 
already at the primary target organ, the tonsils 
[Wilmes and Wolf, 1987]. Some similar 'viral 
strategies' have been suspected for other v i -
ruses. The abundant virus-associated trans-
cripts of adenoviruses for example may as 
well block interferon, permitting adenovi-
ruses to persist in adenoids and elsewhere in 
the human body. 
Little is known about the immortalize 
activity of E B V . L M P has been shown 
change growth behavior of rodent cells [W# 
et al., 1985]. Experiments with human ct 
did induce reduced serum dependence wfr 
transfected into type I B L cells [Henderson 
al., 1991]. In B L this gene is usually 11 
expressed. The same is true for E B N A 
which has interesting transactivating propc 
ties including activation of bcl2 [Hender* 
et al., 1991], which blocks apoptosis, and 
C D 2 3 , the low-affinity IgE receptor. It NN 
have to be tested whether strong viral trans* 
tivators such as B Z L F 1 in analogy to adef 
EIA could play a much more important fl 
than presently appreciated. The observat' 
that B Z L F 1 might be transcribed and tra: 
lated in N P C biopsies by Patton et al. [l9 l 
might point in that direction. 
Even though there is quite a way to 
before we have a coherent picture of even : 
most prominent activities of E B V , we hav' 
do our best to control the most import' 
EBV-related diseases. 
O f special interest is I M , the second fl1, 
frequent disease of young adults (nun^, 
available only for the U S and Denn^ 
[Evans and Niedermann, 1989]. 
Increasing attention is directed to cas^ 
virus activation in transplant recipients vA 
as many as 23% of apparent cases of reject 
crisis may be caused by C M V and E B V ra1 
than by tissue incompatibility. A l t h ^ 
numbers may be relatively low, the fatal 1 
come of E B V infection in patients with ^ 
constitution is an urgent problem when £j 
infection needs to be excluded or control 
O f course, the control of EBV-related rfl^ 
nancies, such as N P C , is a long-term goal } 
will also and finally clarify the causal rela^ 
ship of E B V with these neoplasias. 
Cp 
A A 
CI C2 W1 W2 
240bp •*-
Wp 
WO W1 W2 
210bp 
ORIP 
BKRF1 
BKRF1 
LAT III (LCL) 
Q U 
- 265bp 
B K R F 1 LAT I/II (BL, NPC) 
ORI lyt 
— / / - • • — • • ~ -
WWW W Y H F Q U P O a M S L E e Z R K B G D cb T X Vd B' W' I" A Nhet 
ORI lyt 
. Y , , 
Fig. 5. D rawing of the different promoters used for expression of latent E B N A genes. 
Detection o f these transcripts is possible by R N A - P C R with 5'-upstream primers that are 
specific for the first exons C L WO and F / Q [Kerr et al . , 1992]. A l l three promoters splice to the 
same coding exon for E B N A 1 in the BamHY. fragment up to 100 kbp downstream. Promoters 
C p and W p are giving rise to all latent E B N A transcripts ( L A T III) whereas the F p promoter 
only enables E B N A 1 transcription ( L A T I). 
, In definable high risk groups a vaccine may 
) e highly desirable. For other conditions, pre-
:i*e early diagnosis followed by specific thera-
•}y will be the way to go. For transplant recipi-
ents this becomes quite evident. Considerable 
•vidence suggests that even antiviral therapy 
>[ °Ptimal doses might not be good enough to 
Lpntrol a virus-induced rejection crisis; addi-
l 0 n a l substitution with specific immunoglob-
fhns has been described as a successful proce-
ure. Whether a similar procedure would help 
•ersons susceptible to X L P is yet unclear. 
Early diagnosis alone has been proven to 
; e V e r y successful in areas with extremely 
l ^ h levels of N P C . Rather than detecting 2 
; n d 25% of cases in stages 1 or 2, serological 
^ntrols using detection of IgA antibodies to 
r
i r l>' antigen has pushed these numbers to 40 
^ d 45%, respectively [Zeng et al., 1988, 
1993]. In combination with conventional ra-
diation therapy, early detection dramatically 
decreases the death toll of N P C patients. 
More efficient test systems based on recom-
binant proteins facilitate this approach and 
allow better diagnosis of acute infection 
[Wolf et al., 1985; Gorgievski-Hrisoho et al., 
1990]. For lymphomas, clonality and type of 
proliferating cells are of major importance, 
whereas clonality of virus can be tested via 
Southern blots using restriction enzymes, 
which cut once in the terminal repeats and 
hybridize with appropriate probes [Raab-
Traub and Flynn, 1986]. A definition of cell 
types might be very useful. The restricted 
transcription pattern and promoter usage of 
the E B N A gene family is of particular inter-
est in this context (fig. 5). For Hodgkin's 
lymphomas, in situ hybridization with E B E R 
probes are used increasingly often [Pallesen 
etal., 1991]. 
A vaccine is also in sight now. After exten-
sive work with virus-derived antigens in an 
experimental infection system [Shope et al., 
1973; Werner et al., 1975; Wol f et al., 1975] 
by Epstein, conducted by Morgan and co-
workers [cf. Epstein et al., 1985], the first 
human vaccine trial gave very encouraging 
results [Gu et al., 1993]. The study was per-
formed in China, where only 10-20% of 1-
year-old, but 90% of 3-year-old infants are 
positive for E B V due to natural routes of 
infection. This is an excellent condition for 
evaluation of efficacy for induction of immu-
nity by a vaccine. Two candidate vaccines for 
human use have been developed by our 
group: one is based on purified major mem-
brane protein gp 350/250 (BLLF1 M A ) se-
creted from transfected Chinese hamster ova-
ry cells [Motz et al., 1987]. After the sequence 
encoding the membrane anchor of M A has 
been genetically removed. The viral gene 
stably integrated into the Chinese hams1' 
ovary cells via a transfer vector with dihydr 
folate reductase as a selective marker. Tt 
other vaccine uses recombinant vaccinia vi£ 
(strain Tien Tan), which expresses under tf 
1 lk vaccinia promoter the same viral m^ r 
brane antigen, in this case including the m^ r 
brane anchor. Other vector systems used 1 
eluded yeast with discouraging results, vfl' 
cella virus, baculovirus and other vaccifl1 
based constructs not approved for human u-
The latter life vaccine is already under evafr 
tion for efficacy in China. 60% of vaccina^ 
children have been protected after the first 
months from E B V infection, all control' 
children were infected with E B V through n-
ural routes, as detected by appearance of a^f 
bodies to E A and V C A . Further studies usi 
the purified antigen will follow to identify 1 
least harmful but most effective vaccine. 
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